Form 4: Armata Pharmaceuticals Director, Sarah J. Schlesinger, Acquires Stock Options

Director Sarah J. Schlesinger acquired 54,343 stock options in Armata Pharmaceuticals, Inc. on February 5, 2025.

Summary

• On February 5, 2025, Sarah J. Schlesinger, a director of Armata Pharmaceuticals, Inc., acquired 54,343 stock options.
• The options have an exercise price of $2.04.
• The options vest in two tranches: 50% on February 5, 2026, and the remaining 50% on February 5, 2027, contingent upon continuous service.
• The options expire on February 5, 2035.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative performance, but rather provides transparency.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders and their potential alignment with shareholder interests.

Stakeholder Impact

• Shareholders may view this transaction as a sign of confidence from a company director.

Key Dates